MarginsXMarginsX
Home › Markets › Health Care › DSGN

Design Therapeutics Inc. (DSGN)

DSGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.92
-5.25% on the day
Market cap
$635.2M
Small cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$69.8M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1807120/000119312526098491/0001193125-26-098491-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDSGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001807120
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$69.8M
Operating income-$79.5M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$16.9M
Total assets$226.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
3.1 months
$15.3M cash at September 30, 2026
Share count, 1 year
+12.4%
2025-10-31 to 2026-10-30 · +14.3% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$15.3M cash; operating cash flow -$14.8M a quarter.Report 2026-09-30
Shares outstanding64,036,280 (2026-10-30); 56,963,757 a year earlier; 56,001,992 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-11-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$20.3M-$15.4M$15.3MNo debt tags$010-Q 2026-11-04
Q2 2026
2026-06-30
$0-$20.2M-$15.5M$12.9MNo debt tags$010-Q 2026-08-03
Q1 2026
2026-03-31
$0-$17.6M-$16.4M$12.8MNo debt tags$010-Q 2026-04-28
Q4 2025
2025-12-31
$0-$16.0M-$12.0M$16.9MNo debt tags$010-K 2026-03-09
Q3 2025
2025-09-30
$0-$17.0M-$11.2M$15.1MNo debt tagsNeeds four quarters10-Q 2025-11-05
Q2 2025
2025-06-30
$0-$19.1M-$14.4M$19.7MNo debt tagsNeeds four quarters10-Q 2025-08-07
Q1 2025
2025-03-31
$0-$17.7M-$16.8M$13.7MNo debt tagsNeeds four quarters10-Q 2025-05-07
Q4 2024
2024-12-31
Not filed-$13.7M-$9.9M$22.6MNo debt tags$010-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-04
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 270 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.5%
1 month+7.1%
3 months-27.2%
Year to date+11.6%
1 year+48.3%
From 52-week high-34.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
ABUSArbutus Biopharma Corporation$4.04-1.22%$619.3M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
GERNGeron Corporation$0.9419-2.60%$606.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier